Shaker Investments LLC OH Buys 16,886 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Shaker Investments LLC OH increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 60.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,803 shares of the medical equipment provider's stock after acquiring an additional 16,886 shares during the quarter. Lantheus accounts for about 2.0% of Shaker Investments LLC OH's holdings, making the stock its 10th largest position. Shaker Investments LLC OH owned approximately 0.06% of Lantheus worth $4,917,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Farallon Capital Management LLC lifted its holdings in shares of Lantheus by 595.3% during the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock valued at $92,316,000 after buying an additional 1,269,900 shares during the last quarter. Swedbank AB bought a new stake in shares of Lantheus in the first quarter valued at about $26,346,000. Nomura Holdings Inc. grew its position in Lantheus by 105.3% during the fourth quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider's stock worth $1,282,000 after buying an additional 407,507 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock valued at $121,867,000 after acquiring an additional 394,837 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock valued at $458,271,000 after acquiring an additional 389,828 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of recent research reports. B. Riley upped their target price on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Leerink Partners upped their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target for the company. Truist Financial lowered their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Finally, JMP Securities cut their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Lantheus Trading Up 3.7 %

NASDAQ LNTH traded up $4.02 during trading hours on Friday, hitting $112.19. The company's stock had a trading volume of 486,087 shares, compared to its average volume of 983,696. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $7.78 billion, a P/E ratio of 17.13 and a beta of 0.50. The stock has a fifty day moving average of $104.20 and a 200 day moving average of $89.50.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same quarter in the previous year, the firm posted $1.40 earnings per share. Lantheus's quarterly revenue was up 22.5% compared to the same quarter last year. Equities research analysts forecast that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares of the company's stock, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the transaction, the president now owns 98,980 shares of the company's stock, valued at $9,540,682.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 28,322 shares of company stock valued at $2,731,150. 1.50% of the stock is owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.